Company / Working Capital
Moderna Working Capital History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$4.6B
FY2025
5-year range
$4.6B / $8.5B
FY2021-FY2025
Trend
-22.7%
vs FY2024
Sector context
#9 of 213
Health Care
What the data says
Among 213 Health Care companies, Moderna is in the top 4% for working capital. Working Capital has declined for 3 consecutive years, from $8.5B in FY2022 to $4.6B in FY2025.
Based on SEC 10-K filings.
$4.6B in FY2025 with a 5-year CAGR of +19.0%. Top quartile in the Health Care sector.
Declined from $7.3B to $4.6B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -18.8%
- 5-Year CAGR
- +19.0%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 213This company $4.6B Sector average $934.6M
▼
+387.6% above sector average
Key checks
Key Insights
- Moderna's working capital has declined for 3 consecutive years.
- 5-year CAGR of +19.0%, indicating consistent growth.
- In FY2025, working capital decreased 22.7% year-over-year.
- Ranks #9 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.6B | -22.7% |
| FY2024 | $5.9B | -19.4% |
| FY2023 | $7.3B | -14.1% |
| FY2022 | $8.5B | +22.5% |
| FY2021 | $6.9B | +263.7% |
| FY2020 | $1.9B | +93.7% |
| FY2019 | $985.7M | -26.5% |
| FY2018 | $1.3B | +126.5% |
| FY2017 | $591.8M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026